Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CLDX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Phase I: Glembatumumab Vedotin | Squamous Cell Carcinoma of the Lung | Phase 1/2 · NCT02713828 | Terminated |
| Recombinant Flt3 Ligand | Non-small Cell Lung Cancer (NSCLC) | Phase 2 · NCT02839265 | Completed |
| Glembatumumab Vedotin (CDX-011) | Melanoma | Phase 2 · NCT02302339 | Terminated |
| 6 Melanoma Helper Peptide Vaccine | Melanoma | Phase 1/2 · NCT04364230 | Completed |
| Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Glioblastoma | Phase 2 · NCT03688178 | Active not recruiting |
| Keyhole Limpet Hemocyanin | Glioblastoma | Phase 2 · NCT01498328 | Completed |
| NeoAg-mBRAF | Melanoma | Phase 1/2 · NCT04364230 | Completed |
| Phase II: Glembatumumab Vedotin | Squamous Cell Carcinoma of the Lung | Phase 1/2 · NCT02713828 | Terminated |
| PolyICLC | Melanoma | Phase 1/2 · NCT04364230 | Completed |
| Rindopepimut | Glioblastoma | Phase 2 · NCT01498328 | Completed |
| Trametinib daily Until PD | Melanoma | Phase 1/2 · NCT03580382 | Terminated |
| Unpulsed DCs | Glioblastoma | Phase 2 · NCT03688178 | Active not recruiting |
| Varlilumab (CDX-1127) | Glioblastoma | Phase 2 · NCT03688178 | Active not recruiting |
| Epacadostat | Fallopian Tube Carcinoma | Phase 1/2 · NCT02166905 | Completed |
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Ovarian Clear Cell Adenocarcinoma | Phase 2 · NCT05231122 | Recruiting |
| anti-CD40 antibody (CDX-1140) | Non Small Cell Lung Cancer | Phase 1/2 · NCT04491084 | Terminated |
Also used in these trials (approved or third-party drugs, not CLDX's own candidates): Incomplete Freund's Adjuvant, Pembrolizumab, Poly ICLC, Temozolomide, Bevacizumab, Capecitabine, Nivolumab, Decitabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CLDX holds $650.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.2M/quarter from operations, an estimated runway of 31.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
We believe that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CLDX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Wellington Management Group LLP | Institution (13G, 5%+) | 10,951,399 | 13.94% | 2026-09-30 |
| FMR LLC | Institution (13G, 5%+) | 8,411,905 | 10.71% | 2026-09-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 4,686,187 | 5.97% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,446,795 | 4.39% | 2026-03-31 |
| Samuel Bates Martin SVP AND CFO · +232,815 options |
Insider | 32,942 | 0.04% | 2026-01-02 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL · +168,000 options |
Insider | 30,796 | 0.04% | 2025-12-04 |
| Richard M. Wright Former Officer · +7,875 options |
Insider | 20,833 | 0.03% | 2025-11-13 |
| Ronald Pepin SR. VP & CBO · +45,000 options |
Insider | 20,097 | 0.03% | 2025-12-15 |
Share count 78,545,051 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →